Amid the scramble in Congress to get stuff done before the two-week Easter recess—you know, little things like figuring out how to fund the government and prevent it from shutting down—lawmakers came close to passing what’s known as a national “right-to-try” law.
The House and Senate each passed different versions on a bill that would allow patients to seek unapproved medicines without being subject to safety oversight from the Food and Drug Administration. Thirty-nine states have passed such laws already.
Sen. Ron Johnson (R-Wis.), who’s been leading the national law effort with libertarian think tanks like the Goldwater Institute, said it’s a chance for patients who have no other hope left to take the risk of pursuing an experimental treatment. But opponents, including a group of bioethicists at New York University, have countered that it’s actually a move to undermine the FDA—which already approves more than 99 percent of its expanded access requests—at the risk of endangering patients.
Anyway, my colleagues Alex Ruoff, Bronwyn Mixter, myself and a few others have done a bunch of stories on this, and I started to wonder if/how the right-to-try movement intersects with hospice care. The House version of the bill narrows the definition of eligible patients to those who have six months or less to live, which is one of Medicare’s criteria for meeting hospice eligibility.
Check out what everyone had to say here.
Our graphics team put together a neat set up map on which states have written health-care insurance provisions into their right-to-try laws, which you can check out here:Animated GIF
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)